GLP-1-Exendin-4/IgG4 (Fc) Fusion Protein as a Novel Drug for Diabetes Treatment

Abstract

In this paper, we aimed to look for a potent long acting GLP-1 receptor agonist for diabetes treatment. In this work, we constructed the eukaryotic expression vector of GLP-1-Exendin-4/IgG4 (Fc)-pOptiVEC™-TOPO^® and then transfected it into Chinese hamster ovary DG44 (CHO/DG44) cells using liposome method. Then the beta-cell line INS-1 cells were treated with purified GLP-1-Exendin-4/IgG4 (Fc) fusion protein (0.01, 0.1, 1.0 mM respectively) and randomly assigned to 2 groups, each group were then grown in KRB buffer in the presence of 2.8 mM or 16.8 mM glucose for 2 h separately. In addition, single dose of fusion protein was intraperitoneally injected into male CD1 mice for pharmacokinetic study. Besides, multiple low doses of streptozotozin (STZ) induced diabetes mice were used to evaluate the effect of fusion protein for anti-diabetes in male CD1 mice. GLP-1-Exendin-4/IgG4 (Fc) had stimulatory effect on insulin secretion glucose-dependently from INS-1 cells in a dose-dependent manner. Pharmacokinetic studies showed that the GLP-1 level increased significantly after injecting fusion protein and maintained a higher level for 200 h. Besides, multiple-low-dose STZ-induced diabetes mice which received intraperitoneal injections of fusion protein did not show sign of diabetes. Our results indicated that GLP-1-Exendin-4/IgG4 (Fc) fusion protein retained native GLP-1 activities and had effect on long-term glucose regulation. All the results suggest that this fusion protein may serve as a potent long acting GLP-1 receptor agonist.

Key words

glucagon-like peptide-1 - exendin-4 - GLP-1-Exendin-4/IgG4 (Fc) fusion protein - pharmacokinetic study - streptozotocin (STZ)-induced diabetes mice

^* Yizhang Gan and Ningning Dang contributed equally to this work.

• References

• 1 Liu Y, Gao Z, Guo Q et al. Anti-Diabetic Effects of CTB-APSL Fusion Protein in Type 2 Diabetic Mice. Marine Drugs 2014; 12: 1512-1529
• 2 Wild S, Roglic G, Green A et al. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
• 3 Molitch ME. Current state of type 2 diabetes management. Am J Manag Care 2013; 19: S136-S142
• 4 Schwartz S, Defronzo RA. Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes? The time has come for GLP-1 receptor agonists!. Diabetes care 2013; 36: 2107-2111
• 5 Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology-Endocrinology And Metabolism 2004; 287: E199-E206
• 6 Schäfer S, Tschritter O, Machicao F et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007; 50: 2443-2450
• 7 Meloni A, Deyoung M, Lowe C et al. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes, Obesity and Metabolism 2013; 15: 15-27
• 8 Mudaliar S, Henry R. The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia 2012; 55: 1865-1868
• 9 Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes/Metabolism Research and Reviews 2005; 21: 91-117
• 10 Wu X-M, Ou Q-Y, Zhao W et al. The GLP-1 Analogue Liraglutide Protects Cardiomyocytes from High Glucose-induced Apoptosis by Activating the Epac-1/Akt Pathway. Experimental and Clinical Endocrinology & Diabetes. 2014
• 11 Meier JJ, Nauck MA, Kranz D et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53: 654-662
• 12 Yi L, Yin X, Wei D et al. Expression and purification of exendin-4 dimer in Escherichia coli and its interaction with GLP-1 receptor in vitro. Protein and Peptide Letters 2006; 13: 823-827
• 13 Defronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes care 2005; 28: 1092-1100
• 14 Giorgino F, Natalicchio A, Leonardini A et al. Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications. Diabetes Research and Clinical Practice 2007; 78: S59-S67
• 15 Hadjiyanni I, Baggio LL, Poussier P et al. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 2008; 149: 1338-1349
• 16 Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology 2009; 5: 262-269
• 17 Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism 2003; 88: 3082-3089
• 18 Garber AJ. Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability. Diabetes Care 2011; 34: S279-S284
• 19 Choi J, Diao H, Feng ZC et al. A fusion protein derived from plants holds promising potential as a new oral therapy for type 2 diabetes. Plant Biotechnology Journal 2014; 12: 425-435
• 20 Kim B-J, Zhou J, Martin B et al. Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. Journal of Pharmacology and Experimental Therapeutics 2010; 334: 682-692
• 21 TrüMper A, TrüMper K, Trusheim H et al. Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Molecular Endocrinology 2001; 15: 1559-1570
• 22 Flock G, Baggio LL, Longuet C et al. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007; 56: 3006-3013
• 23 Soltani N, Kumar M, Glinka Y et al. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene therapy 2007; 14: 981-988
• 24 Stiles BL, Kuralwalla-Martinez C, Guo W et al. Selective deletion of Pten in pancreatic β cells leads to increased islet mass and resistance to STZ-induced diabetes. Molecular and cellular biology 2006; 26: 2772-2781
• 25 Kaleem M, Medha P, Ahmed Q et al. Beneficial effects of Annona squamosa extract in streptozotocin-induced diabetic rats. Singapore Medical Journal 2008; 49: 800-804
• 26 Buteau J, Foisy S, Rhodes CJ et al. Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes 2001; 50: 2237-2243
• 27 Chen W-J, Wang L-X, Wang Y-P et al. Exendin-4 Protects MIN6 cells from t-BHP-induced Apoptosis via IRE1-JNK-Caspase-3 signaling. International Journal of Endocrinology 2012;
• 28 Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regulatory peptides 2005; 128: 149-157
• 29 Raman VS, Mason KJ, Rodriguez LM et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010; 33: 1294-1296
• 30 Ma B, Hu X, Zhao X et al. Pharmacokinetics, Pharmacodynamics, and Cytotoxicity of Recombinant Orally-administrated long-lasting GLP-1 and its Therapeutic Effect on db/db Mice. Experimental and Clinical Endocrinology & Diabetes 2014; 122: 215-221
• 31 Wu YL, Huang J, Liu J et al. Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice. Journal of Peptide Science 2011; 17: 499-504
• 32 Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological Research 2001; 50: 537-546